Skip to main content
. 2021 Jan 11;6(1):e143129. doi: 10.1172/jci.insight.143129

Figure 2. CR3022 possesses comparable Fc activity to neutralizing and non-neutralizing SARS-CoV-2 monoclonal antibodies.

Figure 2

(A–D) CR3022 was tested for its ability to drive ADCP (A), ADNP (B), NK cell activation (C), or ADCD (D) compared with other SARS-CoV-2 RBD-targeting monoclonals. For the line graphs, each dot represents the mean of 2 replicates. For NK cell activation, 3 donors were used. For the bar graphs, the values are represented as the AUC of serial dilutions. The dotted line represents the average AUC value for the control EBOV-targeting antibody (KZ52). The error bars represent the standard deviation between the replicates. Significance was determined by an ordinary 1-way ANOVA followed by Tukey’s multiple-comparison test. *P < 0.05, ****P < 0.0001.